FI48973B - - Google Patents

Info

Publication number
FI48973B
FI48973B FI02158/68A FI215868A FI48973B FI 48973 B FI48973 B FI 48973B FI 02158/68 A FI02158/68 A FI 02158/68A FI 215868 A FI215868 A FI 215868A FI 48973 B FI48973 B FI 48973B
Authority
FI
Finland
Application number
FI02158/68A
Other languages
Finnish (fi)
Other versions
FI48973C (en
Inventor
P Hartley
S Gunning
Original Assignee
Fisons Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Pharmaceuticals Ltd filed Critical Fisons Pharmaceuticals Ltd
Application granted granted Critical
Publication of FI48973B publication Critical patent/FI48973B/fi
Publication of FI48973C publication Critical patent/FI48973C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
FI682158A 1967-08-08 1968-07-30 A method of making a readily fluidizable inhalant. FI48973C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB36270/67A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
FI48973B true FI48973B (en) 1974-12-02
FI48973C FI48973C (en) 1975-03-10

Family

ID=10386572

Family Applications (1)

Application Number Title Priority Date Filing Date
FI682158A FI48973C (en) 1967-08-08 1968-07-30 A method of making a readily fluidizable inhalant.

Country Status (14)

Country Link
US (1) US3634582A (en)
JP (1) JPS5643448B1 (en)
BE (1) BE718846A (en)
CA (1) CA946280A (en)
DE (2) DE1792207C3 (en)
DK (1) DK123276B (en)
FI (1) FI48973C (en)
FR (2) FR8142M (en)
GB (1) GB1242211A (en)
IE (1) IE32343B1 (en)
MY (2) MY7400329A (en)
NL (1) NL161984C (en)
NO (1) NO128307B (en)
SE (1) SE372420B (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381872A (en) * 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
BE787100A (en) * 1971-08-06 1973-02-02 Beecham Group Ltd COMPOSITION FOR THE TREATMENT OF ASTHMA
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
DE2332663C2 (en) * 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Use of corticosteroid active ingredients for inhalation therapy
DE2535258C2 (en) * 1974-08-10 1993-06-03 Fisons Plc, Ipswich, Suffolk Inhalable drug in pellet form
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
CY1333A (en) * 1980-04-30 1986-10-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
BE891013A (en) * 1980-11-05 1982-05-05 Fisons Ltd PHARMACEUTICAL COMPOSITIONS
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
JP2770970B2 (en) * 1987-04-09 1998-07-02 フアイソンズ・ピーエルシー Pharmaceutical composition containing pentamidine
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
WO1993025193A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Pharmaceutical preparation for intra-airway administration
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1736B (en) 1993-10-01 1999-12-30 Astra Ab Methods and devices that promote increased particle aggregation
SG48049A1 (en) * 1993-10-01 1998-04-17 Astra Ab Process i
NL9301851A (en) * 1993-10-26 1995-05-16 Cordis Europ Cryo-ablation catheter.
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
DE4425255A1 (en) * 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application
PL321094A1 (en) 1994-12-22 1997-11-24 Astra Ab Parathyroid hormone (pth) containing preparation administered by inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
KR100467058B1 (en) * 1997-05-27 2005-01-24 디렉트-할러 아/에스 Inhaler for powdered medicaments
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
CZ2001584A3 (en) * 1998-08-18 2002-06-12 The Regents Of The University Of California Prevention of phlegm formation in air passages by administering EGF-R antagonists
ITMI991582A1 (en) 1999-07-16 2001-01-16 Chiesi Farma Spa DUST CONSTITUTED FROM PARTICLES HAVING THE PERFECTLY SMOOTH SURFACE FOR USE AS VEHICLES FOR THE PREPARATION OF INALA MIXTURES
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (en) 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
BR0107304A (en) * 2000-10-12 2002-08-13 Boehringer Ingelheim Pharma Inhalation powder containing tiotropium
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10141377A1 (en) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
EP1487417A4 (en) * 2001-09-17 2010-03-17 Glaxo Group Ltd Dry powder medicament formulations
MXPA04004730A (en) * 2001-11-19 2004-07-30 Becton Dickinson Co Pharmaceutical compositions in particulate form.
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (en) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
JP2006516531A (en) * 2002-08-21 2006-07-06 ノートン　ヘルスケアー　リミテッド Inhalation composition
DE10255387A1 (en) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg New tiotropium-containing powder formulation for inhalation
US7763280B2 (en) * 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10317461A1 (en) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE10338402A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried, amorphous BIBN 4096, process for its preparation and its use as inhalant
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
DE10338399A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder
DE10338407A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg New inhalable powders containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US9345664B2 (en) 2003-09-02 2016-05-24 Norton Healthcare Ltd Process for preparing a medicament
PE20050489A1 (en) 2003-11-04 2005-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
WO2005102429A1 (en) 2004-04-21 2005-11-03 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
DE102004048389A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modification of surfaces of lactose as adjuvant for use with powder inhalants
DE102004048390A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg New powder inhalants based on modified lactose mixtures as adjuvant
EP1848444B1 (en) * 2005-02-10 2016-11-09 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
CN103145766B (en) 2008-07-24 2015-02-11 乔治洛德方法研究和开发液化空气有限公司 Heteroleptic cyclopentadienyl transition metal precursors for deposition of transition metal-containing films
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
PT106094A (en) 2012-01-13 2013-07-15 Hovione Farmaciencia S A ADMINISTRATION BY INHALATION OF FORMULATIONS WITH HIGH DOSE
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3054948B1 (en) 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN110305095A (en) * 2013-10-22 2019-10-08 综合医院公司 Cromoglycic acid derivative and the correlation technique of imaging and treatment
PL3125875T3 (en) 2014-04-04 2023-11-20 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
JP6679584B2 (en) 2014-10-07 2020-04-15 エイアイ・セラピューティクス・インコーポレーテッド Inhalable rapamycin formulations for treating pulmonary hypertension
AU2017321782B2 (en) 2016-08-31 2022-03-10 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MX2019014671A (en) * 2017-06-28 2020-02-07 Philip Morris Products Sa Container with particles for use with inhaler.
MX2020000577A (en) 2017-07-20 2020-09-10 Aztherapies Inc Powdered formulations of cromolyn sodium and ibuprofen.
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation Powdered formulations of cromolyn sodium and ?-lactose
EP3910324A1 (en) 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
US20230310363A1 (en) 2020-08-28 2023-10-05 Universität Linz Use of leoligin in the prevention of tissue damage

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792207U (en) 1959-04-14 1959-07-16 Esslinger Sack Und Planenfabri TRANSPORTABLE GARDEN SWIMMING POOL OR POOL WITH WALLS MADE OF PLASTIC FOIL.
FR1489749A (en) * 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd Process for the preparation of bis-chromonyl compounds and their derivatives

Also Published As

Publication number Publication date
MY7400329A (en) 1974-12-31
DE1792207B2 (en) 1977-10-13
BE718846A (en) 1969-01-31
NL161984C (en) 1980-04-15
GB1242211A (en) 1971-08-11
DE1792207A1 (en) 1971-11-04
NL161984B (en) 1979-11-15
FI48973C (en) 1975-03-10
DK123276B (en) 1972-06-05
MY7400330A (en) 1974-12-31
IE32343L (en) 1969-02-08
FR8142M (en) 1970-08-17
JPS5643448B1 (en) 1981-10-13
FR1605538A (en) 1979-02-23
SE372420B (en) 1974-12-23
NO128307B (en) 1973-10-29
DE1792799A1 (en) 1977-08-11
DE1792207C3 (en) 1978-06-29
US3634582A (en) 1972-01-11
IE32343B1 (en) 1973-06-27
NL6811060A (en) 1969-02-11
CA946280A (en) 1974-04-30

Similar Documents

Publication Publication Date Title
FI48973B (en)
AT298283B (en)
AU342066A (en)
AU2277767A (en)
AU3151267A (en)
AU2454867A (en)
AU2528767A (en)
AU2977667A (en)
AU2256867A (en)
AU2116667A (en)
AU1273466A (en)
AU3189468A (en)
BE709303A (en)
AU25066A (en)
BE709212A (en)
AU459699A (en)
BE709150A (en)
BE708919A (en)
BE708895A (en)
BE709617A (en)
AU1677166A (en)
AU23366A (en)
BE710804A (en)
BE705250A (en)
AU2406369A (en)